Icatibant Fresenius

Icatibant acetate, the active ingredient in Icatibant Fresenius, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1 inhibitor deficiency.

GNH USA supplies Icatibant Fresenius as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant Fresenius is used to treat conditions involving bradykinin‑mediated vascular permeability, primarily hereditary angioedema.

- Hereditary angioedema (HAE) with C1‑inhibitor deficiency: Provides rapid relief of acute swelling attacks by blocking the bradykinin B2 receptor. - Hereditary angioedema with normal C1‑inhibitor (HAE type III): Offers symptomatic control during episodic attacks. - Bradykinin‑mediated angioedema (off‑label): May reduce swelling by antagonising B2 receptors.

Icatibant Fresenius may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to HAE: unexpected swelling. - Urticaria: hives or skin rash. - Thrombocytopenia: low platelet count. - Severe allergic reaction: includes bronchospasm or facial swelling.

Before using Icatibant Fresenius, consider the following safety measures.

- Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown safety; assess potential risks. - Renal impairment: no dosage adjustment required, but monitor renal function. - Concomitant ACE inhibitors or ARBs: may increase bradykinin levels; observe for angioedema. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant Fresenius can interact with other medicines that affect the bradykinin pathway or cardiovascular system.

Major Interactions (Avoid): - ACE inhibitors: additive bradykinin effect may increase angioedema risk. - Angiotensin receptor blockers (ARBs): similar risk of enhanced bradykinin activity. - Other B2 receptor antagonists: may potentiate pharmacologic effects.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure for additive hypotensive effect. - Antihistamines: may mask early signs of allergic reactions. - Corticosteroids: no direct interaction but monitor overall immune response.